# Who does Gilead Sciences, Inc. pay? Who are its key suppliers?
Canonical: https://valuechain.wiki/gilead-sciences · Facet: suppliers · Updated: 2026-09-24T12:38:40.858238+00:00 · Source: ValueChain.wiki (cited money-flow graph)

**Citable summary**: Gilead Sciences, Inc.'s confirmed suppliers/cost counterparties include Yuhan Corporation, Shionogi & Co., Cognizant Technology Solutions Corporation plus 1 undisclosed/aggregate relationship. Per the valuechain.wiki graph: 4 cost edges, backed by 7 dated sources, 5 of them primary filings (as of 2026-09-24).

### 유한양행 (high)  → /yuhan.md
- metric: Amount ₩210.2B · HIV 원료 공급계약
- note: Gilead sources HIV and hepatitis C (HCV) active pharmaceutical ingredients from Yuhan Chemical, a Yuhan subsidiary. HIV API contract KRW 210.2bn (US$139.8m, 9.61% of Yuhan's 2025 consolidated revenue, 2026-05-19); HCV API contract KRW 85.0bn (US$61.3m, 2025-08-26).
- [confirms] FSS DART (KO, filing, published 2026-05-20) https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260520800079: "API supply contract. Value KRW 210,191,637,904 (USD 139,810,854), 9.61% of recent revenue KRW 2,186,637,586,358. Counterparty Gilead Sciences. Term 2026-05-19 to 2027-12-31."
- [confirms] FSS DART (KO, filing, published 2026-03-12) https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260312001236: "Overseas segment: exports of HIV/AIDS treatment intermediates etc. KRW 386,541m (17.7%); Yuhan Chemical produces APIs (FTC etc.)."
- [confirms] FSS DART (KO, filing, published 2025-08-27) https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20250827800028: "HCV treatment API supply contract. Value KRW 84,973,258,500 (USD 61,295,000), 4.11% of revenue. Counterparty Gilead Sciences."

### Arcus Biosciences (high)
- metric: Amount $320M · Q1 2024 · Total equity investment for 15.2 million additional Arcus Biosciences common shares
- note: Gilead purchased an additional 15.2 million shares of Arcus Biosciences common stock in 2024 for $21 per share and $320 million in total. The transaction raised its ownership stake to about 33%.
- [confirms] SEC EDGAR (EN, filing, published 2025-02-25) https://www.sec.gov/Archives/edgar/data/1724521/000172452125000040/rcus-20241231.htm: "Gilead purchased 15.2 million shares of our common stock for total gross proceeds of $320 million."
- [confirms] Arcus Biosciences Investor Relations (EN, ir, published 2024-01-29) https://investors.arcusbio.com/investors-and-media/press-releases/press-release-details/2024/Gilead-and-Arcus-Announce-Amended-Collaboration-and-Equity-Investment/default.aspx: "a separate equity investment by Gilead of $320 million in Arcus common stock at $21.00 per share."

### 시오노기제약 (high)  → /shionogi.md
- metric: Amount $112M · FY2025 · Royalties due to Shionogi related to Genvoya and Stribild
- note: Shionogi assumed Japan Tobacco's rights and obligations under the Gilead agreements in 2025. Gilead pays product-sales-based royalties tied to Genvoya and Stribild, recording $112 million of expense in FY2025.
- [confirms] SEC EDGAR (EN, filing, published 2026-02-24) https://www.sec.gov/Archives/edgar/data/882095/000088209526000006/gild-20251231.htm: "We expensed royalties due to Shionogi of $112 million."

### 코그니전트 (high)  → /cognizant.md
- note: Gilead Sciences receives AI-driven solutions from Cognizant for customer service, employee experience, and business value management, and the companies expanded their existing relationship in 2025 without disclosing the contract value.
- [confirms] SEC EDGAR (EN, filing, published 2025-02-05) https://www.sec.gov/Archives/edgar/data/1058290/000105829025000007/exhibit99112312024.htm: "Expanded its longstanding relationship with biopharmaceutical leader Gilead Sciences. Cognizant will provide AI-driven solutions."
- [confirms] Cognizant Investor Relations (EN, ir, published 2025-01-30) https://investors.cognizant.com/news-and-events/news/news-details/2025/Cognizant-and-Gilead-Expand-Partnership-to-Drive-Greater-Value-Through-Advanced-Technology-Applications/: "the work addresses multiple use cases across customer service, employee interactions, and business value management."

### 삼성바이오로직스 (mid)  → /samsung-biologics.md
- metric: Contract value ₩300.5B · 계약 누계 공개액 · Samsung Biologics contract-manufacturing value for Gilead, formerly Immunomedics
- note: A Hana Securities review of Samsung Biologics' supply contracts identifies Gilead as a contract-manufacturing customer. The table records a KRW 300.5 billion contract and notes the 2021 counterparty change and volume increase.
- [confirms] Hana Securities (KO, research, published 2023-01-30) https://www.hanaw.com/download/research/FileServer/WEB/industry/enterprise/2023/01/29/SamsungBiologics_230130.pdf: "The supply-contract table lists Gilead, formerly Immunomedics, with a KRW 300.5 billion contract-manufacturing agreement and notes increased volume."

Reverse side: https://valuechain.wiki/gilead-sciences/customers.md · Ripple: https://valuechain.wiki/gilead-sciences/ripple.md

---
Full node: https://valuechain.wiki/gilead-sciences.md · JSON: https://valuechain.wiki/gilead-sciences.json